Experimental TB Vaccine For HIV-Positive People Enters Phase II Clinical Trials
April 15, 2010
Biopharmaceutical company Crucell and the Aeras Global Tuberculosis Vaccine Foundation announced the start of "Phase II clinical trial of a tuberculosis-vaccine candidate targeted at adults infected with HIV," MarketWatch reports. Trials will test the "safety and efficacy of Aeras 402/Crucell Ad35" and will be led by the Aurum Institute in Klerksdorp, South Africa (Daniel, 4/14).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.